Clinical experience of natalizumab in Crohn's disease patients in a restricted distribution program

BACKGROUND: Natalizumab (NAT) is a humanized monoclonal antibody against a4-integrin initially approved for the treatment of multiple sclerosis, and then withdrawn from the market in 2005 due to the risk of progressive multifocal leukoencephalopathy. NAT was approved for the treatment of Crohn'...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Chien-Huan, Kularatna, Gowri, Stone, Christian D., Gutierrez, Alexandra M., Dassopoulos, Themistocles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hellenic Society of Gastroenterology 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3959435/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3959435/

Ejemplares similares